Business Context and Reporting Period
This Form 6-K filing by EUDA Health Holdings Ltd (EUDA) covers the month of November 2025. The report details a corporate financing transaction rather than periodic financial results. The filing was signed on December 4, 2025.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to the specific transaction described below:
- Transaction Proceeds: $100,000 aggregate purchase price for a convertible warrant.
- Warrant Terms: Immediately exercisable into 2,000,000 ordinary shares at an exercise price of $6.00 per share.
- Expiration: 90 days from issuance (Cash Exercise Period), with potential extension by mutual agreement.
Material Changes
The material change reported is the entry into a Securities Purchase Agreement dated November 26, 2025, with an accredited investor. This transaction introduces new potential equity dilution and specific contractual obligations regarding share issuance and repurchase rights.
Outlook, Risks, and Unusual Items
Transaction Mechanics and Risks:
- Forced Exercise: The Company may require the Purchaser to exercise the Warrant up to 10% of cumulative dollar trading volume if the share price closes at or above $7.50 for five consecutive days and cumulative volume exceeds $1,500,000.
- Repurchase Right: During a two-week Repurchase Period following the Cash Exercise Period, the Company has the right to repurchase remaining Warrant Shares for $0.0625 per share.
- Cashless Exercise: If the Warrant remains outstanding at expiration, the Purchaser is deemed to have made a cashless exercise, receiving one ordinary share for every ten Warrant Shares. In the event of a breach of terms, the ratio improves to one share for every five Warrant Shares.
- Regulatory Status: The transaction is filed under an effective Registration Statement on Form F-3 (File No. 333-282723). The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the impact of the potential 2,000,000 new shares on current shareholder dilution.
- Confirm the Company's ability to meet the $1,500,000 cumulative trading volume threshold required to trigger the Forced Exercise provision.
- Review the full text of the Securities Purchase Agreement (Exhibit 1.1) and Form of Warrant (Exhibit 1.2) for additional covenants not summarized here.
- Check the Company's cash position to ensure it can fund the repurchase of warrants at $0.0625 per share if the Repurchase Right is exercised.